VC  Domain Associates

http://www.domainvc.com





     Office Locations:

One Palmer Square, Suite 515
Princeton, NJ 08542
Phone: 609-683-5656
Fax: 609-683-9789

Get all office locations for this firm with a National Database subscription or Southern California Database subscription.
 

Stages:

  • Early


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Domain Associates was organized in 1985 to focus a group of senior partners with experience in relevant technologies on the many new venture opportunities evolving in life sciences. With over $2.7 billion of capital under management, Domain is headquartered in Princeton, NJ and maintains a second office in San Diego, CA. Companies receiving early venture financing and active involvement from Domain's partners account for over $56 billion of stock market value and close to $5.5 billion in annual revenues. Domain annually provides approximately $100 million to U.S.-based ventures concentrating in the life sciences industries. Domain has been involved in the formation of more than 250 companies over the last 27 years. While the majority of Domain's investments are in private companies, it also invests in some public companies typically characterized by a need to define and implement a new corporate strategy.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Southern California Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Southern California Database subscription.
    Adair Newhall Principal
    Brian H. Dovey Partner
    Brian K. Halak PhD Partner
    Debra Liebert Principal
    Dennis G. Podlesak Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/30/2017


      Fractyl Labs


      MA


      $44,000,000


      Series D


      07/25/2017


      Sebacia


      GA


      $20,000,000


      Series D


      04/29/2017


      Epic Sciences


      CA


      $40,000,000


      Series D


      04/27/2017


      ChromaCode


      CA


      $12,000,000


      Series B


     

    Portfolio companies include:


      Achaogen
        web link


      Achillion Pharmaceuticals
        web link


      Adynxx
        web link


      Afferent Pharmaceuticals
        web link


      Alimera Sciences
        web link


      Apnex Medical
        web link


      Applied Proteomics
        web link


      Aria Diagnostics
        web link


      Ascenta Therapeutics
        web link


      Asmacure
        web link


      Astute Medical
        web link


      Atara Biotherapeutics
        web link


      aTyr Pharma
        web link


      Axial Biotherapeutics
        web link


      Benvenue Medical
        web link


      BioNano Genomics
        web link


      Cadence Pharmaceuticals
        web link


      Carticept Medical
        web link


      Cartiva
        web link


      Celator Pharmaceuticals
        web link


      Celtaxsys
        web link


      ChromaCode
        web link


      Clovis Oncology
        web link


      CoDa Therapeutics
        web link


      Colucid Pharmaceuticals
        web link


      Corridor Pharmaceuticals
        web link


      Dicerna Pharmaceuticals
        web link


      Durata Therapeutics
        web link


      Epic Sciences
        web link


      Esperion Therapeutics
        web link


      Evoke Pharma
        web link


      Five Prime Therapeutics
        web link


      Foundry Newco XII
        web link


      Fractyl Laboratories
        web link


      Fractyl Labs
        web link


      GI Dynamics
        web link


      Glaukos
        web link


      Glaukos Corp
        web link


      Goodwell Tecnhologies
        web link


      IntegenX
        web link


      Iomai
        web link


      Kona Medical
        web link


      Lithera
        web link


      Marinus Pharmaceuticals
        web link


      Meritage Pharma
        web link


      Miramar Labs
        web link


      NeuroPace
        web link


      NovaCardia
        web link


      Obalon Therapeutics
        web link


      OraPharma
        web link


      Oraya Therapeutics
        web link


      Otonomy
        web link


      Pointshare
        web link


      Regado Biosciences
        web link


      REVA Medical
        web link


      ReVision Optics
        web link


      RightCare Solutions
        web link


      ROX Medical
        web link


      Santarus
        web link


      Sebacia
        web link


      SenoRX
        web link


      Sequent Medical
        web link


      SkinMedica
        web link


      Syndax Pharmaceuticals
        web link


      TargetRx
        web link


      Zogenix
        web link


      Zyga Technology
        web link


     

    Recent News: